Direct oral anticoagulants
166 results
51 - 150
Early initiation of direct oral anticoagulants after acute stroke with atrial fibrillation is at least as good as later initiation- Higher risk of bleeding events associated with concomitant use of amiodarone and direct oral anticoagulants
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis- Direct oral anticoagulants are noninferior to low-molecular-weight heparin to prevent recurrent VTE in adults with cancer
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
- Direct oral anticoagulants (DOACs) plus clarithromycin associated with higher risk of bleed than DOACs plus azithromycin
- Direct oral anticoagulants associated with better outcomes than warfarin in older patients with stroke and AF (PROSPER)
Mitral regurgitation - Benefits/harms of novel oral anticoagulants similar in general population and the elderly
- Aortic stenosis
- Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
- Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis
- Concomitant use of oral anticoagulants and SSRIs associated with increased risk of major bleeding
- The DOAC score determines bleeding risk for patients with atrial fibrillation who take a direct-acting oral anticoagulant
- Indications for and implementation of anticoagulant therapy in atrial fibrillation
- Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
- Antithrombotic agents in primary health care
- ACCP guidelines for antithrombotics in atrial fibrillation
- Elevated INR (> 1.5) at admission associated with increased mortality in hospitalized patients who use DOACs
- A new bleeding risk score predicts major bleeding better than other scores in elderly patients who take DOACs
- Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions
- Aspirin no different than rivaroxaban for prevention of VTE after TKA or THA
- For device-detected atrial fibrillation, anticoagulation decreases stroke risk (NNT = 100), increases major bleeding (NNTH = 62)
- Tranexamic acid in people on anticoagulants undergoing minor oral surgery or dental extractions
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
- Adults with atrial fibrillation who survive ICH and resume DOACs have fewer strokes but more recurrent ICH (PRESTIGE-AF)
- Updated American College of Chest Physicians guideline on antithrombotic therapy for venous thromboembolism
- Heart valve operation: patient follow-up and complications
- Use of antithrombotic medications increases risk of hematuria-related complications
- No benefit to continuing perioperative oral anticoagulation for patients undergoing transcatheter aortic-valve implantation
- Resuming oral anticoagulants after a bleed is associated with fewer thrombi and deaths, but more bleeds
- Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
- Anticoagulant therapy for 6 weeks is noninferior to 3 months for provoked VTE in patients younger than 21 years (Kids-DOTT)
- Prevention of venous thromboembolism
- Warfarin therapy
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Oral anticoagulation for prolonging survival in patients with cancer
- Guidelines for the perioperative management of anticoagulants and antiplatelet agents (ACCP)
- Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery
- Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
- Deep vein thrombosis
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
- Pentasaccharides for the prevention of venous thromboembolism: Cochrane systematic review
- Older patients with atrial fibrillation treated with DOACs have fewer strokes and systemic emboli than those treated with vitamin K antagonists
- Benefits and harms with oral anticoagulation for atrial fibrillation in patients with history of intracranial hemorrhage (COCROACH)
- Superficial venous thrombophlebitis
- Nephrotic syndrome
- Rivaroxaban is noninferior to warfarin for valvular atrial fibrillation; also associated with fewer strokes
- Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
- Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
- Edoxaban as effective as LMWH for treatment of cancer-associated VTE
- Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Greater risk of serious bleeding with diltiazem vs metoprolol in adults with atrial fibrillation using apixaban or rivaroxaban
- Abelacimab has fewer bleeds than rivaroxaban, but study has several important biases
- Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
- Vitamin K for improved anticoagulation control in patients receiving warfarin
- Extended rivaroxaban prophylaxis following a medical inpatient stay does not provide a net benefit (MARINER)
- Warfarin provides greater net benefit than rivaroxaban for patients with atrial fibrillation and rheumatic heart disease
- ACG guideline on managing acute lower gastrointestinal bleeding
- Optimal treatment of acute venous thromboembolism
- Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction): Cochrane systematic review
- Assessment and treatment of a patient with bleeding diathesis
- Systemic lupus erythematosus (SLE)
- Electrical cardioversion